Close Menu

Leonardo Biosystems

Arrowhead Research this week reported its fiscal fourth-quarter financial results, posting a higher net loss amid increased operating expenses.
The company also said that efforts to integrate its subsidiaries into a single company are underway.

Leonardo Biosystems said this week that it has received the second half of a $2.5 million grant from the Texas Emerging Technology Fund to help develop its multi-stage drug-delivery technology.
The first half of the grant was received in April 2010.

Arrowhead Research has appointed Bruce Given as its COO.

Mauro Ferrari

Leonardo, which had been expecting the funding, intends to use the money to ramp up its operations with the goal of securing industry partnerships around its so-called multi-stage delivery approach.

While the company may at some point down the road dip its toes into the drug-development waters, "initially, I don't see us having any in-house discovery efforts," Leonardo CEO Bruce Given said.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.